| Literature DB >> 33664494 |
Rita E Chen1,2, Xianwen Zhang3, James Brett Case1, Emma S Winkler1,2, Yang Liu3, Laura A VanBlargan1, Jianying Liu4,5, John M Errico2, Xuping Xie3, Naveenchandra Suryadevara6, Pavlo Gilchuk6, Seth J Zost6, Stephen Tahan7, Lindsay Droit7, Jackson S Turner2, Wooseob Kim2, Aaron J Schmitz2, Mahima Thapa2, David Wang7, Adrianus C M Boon1,2,7, Rachel M Presti1, Jane A O'Halloran1, Alfred H J Kim1, Parakkal Deepak1, Dora Pinto8, Daved H Fremont2,9, James E Crowe6,10, Davide Corti8, Herbert W Virgin2,11,12, Ali H Ellebedy13,14,15, Pei-Yong Shi16,17,18, Michael S Diamond19,20,21,22.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly introduced antibody and vaccine countermeasures. Here, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, we report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants including a B.1.1.7 isolate, chimeric strains with South African or Brazilian spike genes and isogenic recombinant viral variants. Many highly neutralizing mAbs engaging the receptor-binding domain or N-terminal domain and most convalescent sera and mRNA vaccine-induced immune sera showed reduced inhibitory activity against viruses containing an E484K spike mutation. As antibodies binding to spike receptor-binding domain and N-terminal domain demonstrate diminished neutralization potency in vitro against some emerging variants, updated mAb cocktails targeting highly conserved regions, enhancement of mAb potency or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33664494 PMCID： PMC8058618 DOI： 10.1038/s41591-021-01294-w
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 87.241